# Arvinas, Inc

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/Arvinas, Inc).

## Overview

Arvinas, Inc. is a clinical-stage biotechnology company built around its PROTAC protein-degradation platform, which is designed to selectively remove disease-causing proteins rather than just inhibit them. The company’s lead program, vepdegestrant (ARV-471), is an oral estrogen receptor degrader being co-developed with Pfizer for ER+/HER2- breast cancer. Beyond oncology, Arvinas is advancing additional degrader programs in neuroscience and other disease areas, while also building a patent estate around targeted protein degradation. The business is still pre-commercial for its own pipeline, so value creation depends on clinical progress, partnering, and eventual regulatory approvals.

## Products & services

• Vepdegestrant (ARV-471) oral PROTAC ER degrader
• ARV-102 clinical-stage degrader program
• ARV-806 clinical-stage degrader program
• ARV-393 clinical-stage degrader program
• ARV-027 clinical-stage degrader program
• ARV-6723 and pan-KRAS degrader research programs
• PROTAC platform and partnered discovery capabilities

- **Clinical-stage oncology programs** (70%) — Drug candidates aimed at hormone-driven and other cancer targets, including vepdegestrant and other oncology degraders.
- **Neuroscience and inflammatory programs** (15%) — Protein-degradation programs targeting central nervous system and inflammatory disease pathways.
- **Research-stage discovery programs** (10%) — Early-stage internal discovery assets such as pan-KRAS and other preclinical degrader programs.
- **Collaboration and licensing revenue** (5%) — Upfront payments, milestones, and cost-sharing arrangements from partners such as Pfizer and Genentech.

- Vepdegestrant (ARV-471) oral PROTAC ER degrader
- ARV-102 clinical-stage degrader program
- ARV-806 clinical-stage degrader program
- ARV-393 clinical-stage degrader program
- ARV-027 clinical-stage degrader program
- ARV-6723 and pan-KRAS degrader research programs
- PROTAC platform and partnered discovery capabilities

## Customers

Arvinas does not sell commercial medicines broadly today; its current economic counterparties are primarily pharmaceutical partners and, eventually, patients and prescribers if its programs are approved. Pfizer is the most important collaborator because it co-develops vepdegestrant and shares development economics, while also holding marketing authorizations outside the United States. Genentech is another strategic partner through co-owned patent families and licensing arrangements. In the future, the company expects oncology specialists, hospitals, and specialty pharmacies to be the end-market channel for approved products, with commercialization likely supported by partners outside the U.S. and potentially by Arvinas’ own sales force in the U.S. for selected products.

- **Pharmaceutical collaboration partners** (primary) — Large pharma partners buy access to Arvinas’ platform, shared development rights, and co-owned assets to de-risk pipeline development and expand their oncology portfolios.
- **Oncology patients and treating physicians** (primary) — If approved, patients with ER+/HER2- breast cancer and their oncologists would use vepdegestrant and related therapies as targeted treatment options.
- **Specialty care providers and health systems** (secondary) — Hospitals, cancer centers, and specialty pharmacies would dispense and administer approved products and support access and reimbursement.
- **Research collaborators and licensors** (secondary) — Academic and industry partners participate in patent co-ownership, discovery, and licensing arrangements that support the platform and broaden target coverage.

- Pfizer as co-development and commercialization partner for vepdegestrant
- Genentech as a licensing and patent collaboration counterparty
- Future oncology prescribers treating ER+/HER2- breast cancer
- Future specialty pharmacies and hospital systems for approved therapies
- Potential ex-U.S. regional partners for commercialization and distribution
- Research and development collaborators that fund or de-risk pipeline work

## Geography

Arvinas is headquartered in the United States and currently books sales in the U.S. for vepdegestrant if approved, while Pfizer holds marketing authorizations outside the United States. The company’s commercial model is therefore split between U.S. self-commercialization rights and ex-U.S. partner-led commercialization, which reduces the need for a global sales infrastructure. Its intellectual property footprint is broad, with trademark and patent registrations across the U.S., Europe, Japan, China, and several other jurisdictions, reflecting the global nature of drug development and patent protection. Because the business is still clinical-stage, geography matters more for regulatory rights, IP protection, and future launch sequencing than for current revenue concentration.

- United States is the home market and the place where Arvinas expects to book vepdegestrant sales
- Pfizer holds marketing authorizations outside the United States under the collaboration
- IP protection spans the U.S., EU, Japan, China, and other major pharma markets
- Commercialization outside the U.S. is expected to rely on partners rather than a full Arvinas sales force
- Geographic exposure is driven by regulatory approvals and patent enforcement, not current product sales

## Strategy

Arvinas’ strategy is to convert its PROTAC platform into clinically validated, partnerable medicines, starting with vepdegestrant and then extending into additional oncology and neuroscience programs. The company is prioritizing clinical execution, because proof-of-concept data and regulatory milestones are the main value drivers in a pre-commercial biotech model. It is also using collaborations to share development cost and broaden commercialization reach, especially outside the United States where Pfizer will lead marketing authorization. At the same time, Arvinas is investing in intellectual property, manufacturing relationships, and internal capabilities so it can support future launches and preserve optionality on whether to commercialize certain products itself in the U.S.

- **Advance vepdegestrant to approval** (short-term) — The lead asset is the clearest path to first commercial value and validates the PROTAC platform in a major oncology indication.
- **Broaden the pipeline beyond the lead asset** (medium-term) — A diversified set of clinical and preclinical programs reduces dependence on one molecule and expands the platform’s addressable market.
- **Preserve capital and extend runway** (short-term) — As a clinical-stage company with no product sales, funding discipline is essential to keep multiple programs moving through data readouts.
- **Strengthen IP and partnering optionality** (medium-term) — Patent coverage and collaboration structures are central to monetizing the platform and defending future products.

- Advance vepdegestrant through clinical development and regulatory review
- Expand the pipeline in oncology, neuroscience, and other disease areas
- Use partnerships to share development costs and commercialization risk
- Protect and extend the PROTAC intellectual property estate
- Maintain flexibility to self-commercialize selected U.S. products
- Build manufacturing and supply-chain relationships for clinical and future commercial supply

## Risks

Arvinas faces the classic risks of a clinical-stage biotech company: clinical trial failure, regulatory delay, and the possibility that its product candidates never reach commercialization. The company also depends heavily on collaboration economics, especially with Pfizer, so changes in partner priorities, development decisions, or commercialization plans could materially affect future value. Because it has not yet generated product sales, it will likely need additional capital over time, and unfavorable financing conditions could dilute shareholders or force program delays. More broadly, the company operates in a highly competitive and patent-intensive industry where larger pharmaceutical companies and other protein-degradation developers are pursuing similar targets and where intellectual property disputes can be costly and disruptive.

- **Pipeline clinical failure** [critical] — The company’s value depends on proving that its PROTAC candidates are safe and effective in humans; negative data would reduce or eliminate commercialization prospects.
- **Dependence on collaboration partners** [high] — Pfizer shares development costs and controls ex-U.S. marketing authorization for vepdegestrant, so partner decisions directly affect timing and economics.
- **Additional financing need** [high] — The company expects continued operating losses and no near-term product sales, which can require equity issuance or other financing on uncertain terms.
- **Patent and IP disputes** [high] — The business is built on proprietary protein-degradation chemistry and co-owned patent families, making IP challenges a central operating risk.

- Clinical failure risk across lead and pipeline programs
- Regulatory approval risk for vepdegestrant and other candidates
- Dependence on Pfizer and other collaborators for funding and commercialization
- Need for additional capital before product sales are established
- Patent litigation and freedom-to-operate risk in a crowded biotech field
- Competition from larger pharma and other protein-degradation developers
- Manufacturing and supply-chain execution risk for clinical and future commercial supply

## Accounting

The most important accounting issue for Arvinas is revenue recognition from collaboration arrangements, because reported revenue is driven by upfront payments, milestone events, and cost-sharing rather than product sales. That makes quarterly and annual revenue inherently lumpy and less predictive of underlying operating momentum than in commercial-stage pharma companies. Research and development expense is another key area because the company capitalizes little of its discovery work and instead expends heavily on clinical trials, CROs, CMOs, and preclinical synthesis, so small changes in program timing can move reported losses materially. The company also relies on significant estimates for stock-based compensation, restructuring charges, and deferred tax assets, including a full valuation allowance against tax benefits because it does not expect to realize them in the near term.

- **Collaboration revenue recognition** — Can create large swings in quarterly revenue and margins
- **Research and development expense estimation** — Directly affects operating loss and comparability across periods
- **Stock-based compensation** — Affects both R&D and G&A expense presentation
- **Deferred tax assets and valuation allowance** — Limits recognition of tax benefits on the balance sheet

- Collaboration revenue depends on upfront fees, milestones, and cost-sharing
- Revenue can be volatile quarter to quarter because it is not driven by product sales
- R&D expense is highly sensitive to clinical trial timing and outsourced development spend
- Stock-based compensation affects both R&D and G&A expense levels
- Deferred tax assets are fully offset by a valuation allowance due to cumulative losses
- Restructuring and other one-time charges can distort year-over-year comparisons

---

*Last updated: 2026-09-24T11:19:49.661391+00:00*